In frail patients with a hip fracture who are not eligible for surgery: a prospective multicenter cohort study

Published: 20-05-2021
Last updated: 07-09-2024

PENG block with phenol provides better pain relieve and mobility, and therefore quality of life, compared to current pain relieve strategies in patients with a hipfracture who are not eligible for surgery

Ethical review	Positive opinion
Status	Recruiting
Health condition type	Bone and joint therapeutic procedures
Study type	Observational non invasive

Summary

ID

NL-OMON24402

Source
NTR

Brief title
PENG block in hip fractures

Condition

- Bone and joint therapeutic procedures

Health condition

Hip fractures

Research involving
Human

Sponsors and support

Primary sponsor: Radboudumc

Secondary sponsors:	ZonMw
Source(s) of monetary or material Support:	None

Intervention

- Other intervention

Explanation

Pericapsular Nerve Group Block with Phenol

Outcome measures

Primary outcome

Quality of life

Secondary outcome

- Mobility (direct, after 1 and 4 weeks and 3 months - Mortality (30 days, in hospital, 1 year) - NRS before and directly after, after 1 and 4 weeks or PACSLAC-D before vs directly after, after 1 and 4 weeks - opioid consumption - treatment satisfaction of patient (or proxy) and caregivers (1-10) - quality of dying (QODD) - time to death (in days to months) - Complications

Study description

Background summary

In the Netherlands, it is estimated that annually 17.500 patients are admitted to the hospital with a hip fracture. 3% of this population is not eligble for surgery. Pain treatment is often insufficient and with significant side-effects in this frail population. The PENG block with administration of phenol might be a better and longer lasting alternative, thereby improving mobility and nursing care with less complications.

Study objective

PENG block with phenol provides better pain relieve and mobility, and therefore quality of life, compared to current pain relieve strategies in patients with a hipfracture who are not eligible for surgery

Study design

At ward admittance, after intervention, after 1 and 4 weeks, after 3 months

Intervention

Neurolytic (modified) PEricapsular Nerve Group block / hip denervation with ultrasound guidance

Contacts

Public
Radboudumc
Rachel Smits

+31628934830
Scientific
Radboudumc
Rachel Smits

+31628934830

Eligibility criteria

Age
Adults (18-64 years)
Adults (18-64 years)
Elderly (65 years and older)
Elderly (65 years and older)

Inclusion criteria

- Clinical patients not eligible for surgery conform standard shared decision - Caput-, collum- and pertrochanteric fractures - Informed consent of patient or by proxy

Exclusion criteria

- Subtrochanter and more distal femur fractures - acetabelum fracture - periprostethic fractures - No informed consent

Study design

Design

Study phase:	N/A
Study type:	Observational non invasive
Intervention model:	Single
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown
Primary purpose:	Supportive care

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	18-08-2023
Enrollment:	150
Type:	Actual

IPD sharing statement

Plan to share IPD: Yes

Ethics review

Positive opinion

Date:	16-11-2022
Application type:	First submission
Review commission:	METC Oost-Nederland p/a Radboudumc, huispost 628, Postbus 9101 6500 HB Nijmegen 024 361 3154

commissiemensgebondenonderzoek@radboudumc.nl

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL9487

Study results